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Genetic deficiency of Jak3 leads to abrogation of
signal transduction through the common gamma
chain (gc) and thus to immunodeficiency suggesting
that specific inhibition of Jak3 kinase may result in
immunosuppression. Jak1 cooperates with Jak3 in
signaling through gc-containing receptors. Unex-
pectedly, a Jak3-selective inhibitor was less efficient
in abolishing STAT5 phosphorylation than pan-Jak
inhibitors. We therefore explored the roles of Jak1
and Jak3 kinase functionality in signaling using a re-
constituted system. The presence of kinase-inactive
Jak1 but not kinase-inactive Jak3 resulted in
complete abolishment of STAT5 phosphorylation.
Specific inhibition of the ‘‘analog-sensitive’’ mutant
AS-Jak1 but not AS-Jak3 by the ATP-competitive
analog 1NM-PP1 abrogated IL-2 signaling, corrobo-
rating the data with the selective Jak3 inhibitor.
Jak1 thus plays a dominant role over Jak3 and these
data challenge the notion that selective ATP-
competitive Jak3 kinase inhibitors will be effective.
INTRODUCTION
The physiological effects of interleukins (IL)-2, IL-4, IL-7, IL-9,
IL-15, and IL-21 are initiated by binding of these cytokines to
their cognate receptor which triggers a complex signal trans-
duction cascade. All these cytokines utilize receptors containing
the common gamma chain (gc, CD132) which is paired with
a corresponding a chain (for IL-4, -7, -9, -21) or b chain (for
IL-2 and IL-15) which determine ligand specificity. IL-2 and
IL-15 receptors also contain a nonsignaling a chain. Work per-
formed in the last two decades established that Janus kinases
(Jak) 1 and 3 are essential tyrosine kinases associated with
the intracellular domains of the above-mentioned cytokine
receptors with Jak3 binding to gc and Jak1 to the other chain
(Benczik and Gaffen, 2004; Gaffen, 2001; Imada and Leonard,314 Chemistry & Biology 18, 314–323, March 25, 2011 ª2011 Elsevie2000; Johnston et al., 1994, 1996; Kawamura et al., 1994;
Oakes et al., 1996). While Jak1 is widely expressed and is
part of the signaling apparatus of several cytokine receptors,
Jak3 expression is restricted to cells of the hematopoietic
lineage and is coexpressed and exclusively associated with
gc. Loss-of-function mutations in either gc or Jak3 in humans
or experimental deletion of either one of these in mice result
in severe combined immunodeficiency (Cao et al., 1995;
DiSanto et al., 1995; Notarangelo et al., 2000; Rodig et al.,
1998; Thomis et al., 1995) indicating the importance of this
pathway in the establishment and maintenance of a functionally
competent immune system (O’Shea et al., 2004a). Thus, it has
been assumed that inhibitors of signal transduction through
gc/Jak3, in particular, selective inhibitors of the Jak3 kinase
activity, might be effective immunosuppressive drugs with
a potentially improved safety profile compared with drugs
targeting other mechanisms (Borie et al., 2004; O’Shea et al.,
2004b, 2005; Pesu et al., 2005, 2008).
Signaling through gc cytokines, however, also requires Jak1.
Cells lacking either Jak3 or Jak1 are unable to respond to gc
cytokines (Rodig et al., 1998; Thomis et al., 1995). Although
differences in the biochemical steps associated with cytokine
receptor-triggered signal transduction have been described, it
has been assumed that both Jak kinases are equally important
for signal transduction. (Chen et al., 2000; Cheng et al., 2008;
Fujii, 2008; Kirken et al., 1995; Liu et al., 1997; Zhou et al.,
1997). Several low molecular weight Jak inhibitors have been
reported recently which potently inhibit kinase activity in vitro
and cellular responses to cytokines (reviewed in Haan et al.,
2010; Pesu et al., 2008). One such inhibitor, CP-690,550, has
been described to be effective in models of autoimmune
diseases, transplant rejection, and inflammation, suggesting
the importance of this signaling pathway and its therapeutic
potential (Kudlacz et al., 2004, 2008). Clinical trials with Jak
inhibitors are underway with CP-690,550 being currently as-
sessed in multiple indications (http://clinicaltrials.gov). Although
originally described as being selective for Jak3 (Changelian
et al., 2003), CP-609,550, also potently inhibits Jak1 (Jiang
et al., 2008; Karaman et al., 2008; Williams et al., 2009) and
thus efficacy could be determined by the combined inhibition
of both kinases. Therefore, it is not elucidated whether inhibitionr Ltd All rights reserved
Figure 1. si-RNA Knockdown of Jak1
or Jak3 Abrogates IL-2-Induced and
Jak3A572V-Dependent Constitutive STAT5
Phosphorylation
(A) Kit225 and CMK cells were transfected with si-
RNA specific for Jak1 or Jak3 or a scrambled
control si-RNA. Western blots of lysates were
probed with Jak1 and Jak3 antibodies.
(B) STAT5 and STAT1 phosphorylation was
assessed by flow cytometry in Kit225 cells stim-
ulated with IL-2 (left panel) or IFN-a (middle panel)
or in unstimulated CMK cells (right panel). The
cells were treated with si-RNAs as indicated and
the graph shows the standard deviations for three
to four experiments.
Chemistry & Biology
Jak1 Has a Dominant Role over Jak3of Jak3 kinase activity is sufficient to efficiently suppress
gc cytokine signaling as inferred from the phenotype of the
gc and Jak3 deficiencies.
Given the importance of this pathway and intrigued by obser-
vations that selective inhibitors of Jak3 kinase showed unex-
pectedly poor cellular potency in cellular assays involving
signaling through gc (Thoma et al., 2011), we set out to further
explore the relative contributions of Jak1 and Jak3 in gc cytokine
signaling. For this, we generated a reconstituted IL-2 signaling
system in which we studied combinations of different mutations
in Jak1 and Jak3. We demonstrate that, surprisingly, the two Jak
kinases are not of equal importance in IL-2 signal transduction.
Our data indicate that the contribution of Jak1 kinase function-
ality is dominant while Jak3 kinase activity is subordinate and
its activity merely enhances the effect of Jak1.RESULTS
Knockdown of Jak1 or Jak3 with si-RNA Abrogates
IL-2-Dependent and Jak3A572V-Mediated Constitutive
STAT5 Phosphorylation
To interrogate whether Jak1 is required for signal transduction
initiated by IL-2 or through constitutively active Jak3, we selec-
tively depleted either Jak1 or Jak3 by specific si-RNAs in the
human T lymphoma line Kit225 (expressing Jak1WT and
Jak3WT) and in the human acute megakaryocytic leukemia cell
line CMK which expresses a constitutively active mutant of
Jak3 (Jak3A572V) (Walters et al., 2006) and does not require
IL-2 for STAT5 phosphorylation. Each si-RNA downregulated
its specific target efficiently in both cell lines as assessed by
western blot analysis (Figure 1A). The functional consequence
of the specific downregulation of either Jak was probed bymoni-
toring IL-2-dependent (in Kit225 cells) or constitutive (in CMK
cells) phospho-STAT5 (P-STAT5) by flow cytometry. In bothChemistry & Biology 18, 314–323, March 25, 2011cell lines, either Jak1 or Jak3 si-RNA
markedly reduced STAT5 phosphoryla-
tion (Figure 1B). As a control, IFN-
a-induced STAT1 phosphorylation (which
is known to be dependent on Jak1 and
Tyk2 but does not involve Jak3) was
only reduced by Jak1 si-RNA but not by
Jak3 si-RNA in Kit225 cells. Thus, in IL-2-dependent signaling as well as in signaling through the consti-
tutively active mutant Jak3A572V, both Jak1 and Jak3 proteins
are required. Constitutively catalytically active Jak3 is insufficient
to lead to STAT5 phosphorylation in the absence of Jak1.
Specific Inhibition of Jak3 Kinase Activity Is Less
Effective in Blocking IL-2-Dependent Phosphorylation
of STAT5 and Other Signaling Molecules than pan-Jak
Inhibition
Three kinase inhibitors (structures shown in Table 1) with activity
against Jak family members were tested in enzyme assays with
kinase domains of the four Jaks. In agreement with literature
data (Changelian et al., 2003; Karaman et al., 2008; Thompson
et al., 2002; Williams et al., 2009), CP-690,550 and Jak inhibitor
I showed no significant selectivity for Jak3 over Jak1. NIBR3049
(Thoma et al., 2011) selectively inhibited Jak3 at low nanomolar
concentrations and showed greater than 150-fold selectivity
over the other Janus kinases (Table 1).
The effect of the three compounds was investigated on IL-2 or
IFN-a-dependent stimulation of STAT phosphorylation in CMK
cells and the human T lymphoma line Kit225. CMK cells were
investigated for basal P-STAT5 and for IFN-a-induced
P-STAT1. STAT5 and STAT1 phosphorylation were measured
by flow cytometry with phosphospecific antibodies (Table 2A).
In agreement with the enzymatic data, CP-690,550 and Jak
inhibitor 1 efficiently inhibited both cytokine-induced and consti-
tutive STAT phosphorylation. NIBR3049 showed poor activity on
signaling induced by IFN-a, in agreement with its poor potency
toward Jak1, Jak2, and Tyk2. Surprisingly, the concentrations
of the Jak3-specific compound NIBR3049 needed to suppress
IL-2-dependent (Kit225) or constitutive (CMK) STAT5 phosphor-
ylation were 20 to 50 fold higher compared with the pan-Jak
inhibitors despite similar potencies in the Jak3 kinase assay.
NIBR3049 also less efficiently inhibited other signaling pathways
activated by IL-2 in Kit225 cells (see Figure S1 and Table S1ª2011 Elsevier Ltd All rights reserved 315
Table 1. Characterization of the Jak Inhibitors Used in This Study
Inhibitor IC50 in Enzymatic Assay (nM)
Structure Denomination Tyk2 Jak1 Jak2 Jak3
N
N O
N
N
N
H
N
CP-690,550 176 ± 25 6.1 ± 2 12 ± 2 8.0 ± 2
NH
N
NH
O
F
Jak inhibitor 1 7 ± 0.5 5.2 ± 0.4 4.5 ± 0.5 41 ± 4.1
N
N
H
N
H
F
3
C
O
O
N
O
OH
NIBR3049 8055 ± 589 1017 ± 117 2550 ± 326 8.0 ± 2
IC50 values of the Jak inhibitors in enzyme assays are reported in nM as the average ± SEM of at least three experiments. Kinase activities were
assessed against synthetic peptide substrates using the Caliper technology and were carried out as described in Experimental Procedures.
Chemistry & Biology
Jak1 Has a Dominant Role over Jak3available online). The phosphorylation of STAT1 and STAT3
(which is also induced upon IL-2 albeit at much lower levels
than STAT5) as well as of Erk1/2 and Akt, was inhibited at lower
concentrations by the pan Jak inhibitor CP-690,550 compared
with the selective Jak3 inhibitor NIBR3049.
CP-690,550 and NIBR3049 showed similar passive perme-
ability, a measure indicating cell penetration (Wohnsland and
Faller, 2001), and determinations of the intracellular concentra-
tions of the two compounds indicated similar levels in CTLL cells
(Thoma et al., 2011). Thus, the differences observed when
comparing the Jak3-specific inhibitor to the pan-Jak inhibitors
are not due to a lower intracellular availability of the Jak3-specific
compound.
We next explored whether this pattern of activity applies to
other cytokines utilizing gc-containing receptors and used
primary human lymphocytes activated with anti-CD3 and
anti-CD28 and expanded in the presence of IL-2. As shown in
Table 2B, the pan–Jak inhibitors potently inhibit STAT5phosphor-316 Chemistry & Biology 18, 314–323, March 25, 2011 ª2011 Elsevieylation induced in these cells by IL-2 and IL-15 as well as STAT6
phosphorylation induced by IL-4 (all three cytokines using recep-
tors which utilize gc) while the Jak3-specific inhibitor NIBR3049
was less active. The response to IFN-a in these cells was similar
to that seen in the cell lines shown in Table 2A. The striking differ-
ence in potency of pan-Jak inhibitors compared with a Jak3-
selective inhibitor in preventing STAT5 phosphorylation was also
seen in themouse T cell line CTLL-2 upon IL-2 stimulation (Thoma
et al., 2011) and the human acutemegakaryoblastic leukemia line
M-07e stimulated with IL-15 (see also Figure S1 and Table S1).
Jak1 Kinase Activity Is Required for STAT5
Phosphorylation by IL-2 or Constitutively Active Jak3
The si-RNA experiments are not informative whether presence of
Jak3 protein as such is needed (to act as a scaffold) or whether
its catalytic activity is mandatory to ‘‘support’’ Jak1 activity. The
data obtained with small molecule inhibitors suggested that
a selective Jak3 antagonist is much less potent at inhibitingr Ltd All rights reserved
Table 2. Inhibition of STATPhosphorylation by Jak Inhibitors in
(A) CMK and Kit225 Cells and (B) Human PBL
A
Cell Line CMK Kit225
Stimulation None IFN-a IL-2 IFN-a
Readout P-STAT5 P-STAT1 P-STAT5 P-STAT1
CP-690,550 90.5 ± 15 199.0 ± 34 26.6 ± 2 32.3 ± 8
Jak inhibitor 1 63.4 ± 8 101.7 ± 12 34.8 ± 12 33.8 ± 1
NIBR3049 2126.8 ± 282 >20,000 738.1 ± 43 4933.3 ± 97
B
Stimulation IL-2 IL-4 IL-15 IFN-a
Readout P-STAT5 P-STAT6 P-STAT5 P-STAT1
CP-690,550 53.0 ± 7 92.8 ± 27 93.7 ± 29 60.2 ± 9
Jak inhibitor 1 55.7 ± 8 57.0 ± 12 62.3 ± 16 24.7 ± 5
NIBR3049 1232.7 ± 50 1067.0 ± 131 1460.7 ± 445 5070.3a
IC50 values in nM are indicated (three to eight independent experiments).
See also Figure S1 and Table S1.
a Average of two measurements.
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about equipotent on Jak1 and Jak3, but they do not unambigu-
ously prove that NIBR3049 inhibited Jak3 kinase function in
a cellular context. To further investigate the mechanisms under-
lying these observations, we reconstituted IL-2 signaling in U4C
cells (Kohlhuber et al., 1997) which are devoid of IL-2 receptor
chains as well as Jak1 and Jak3. First, we generated stable
transfectants expressing IL-2Rb and IL-2Rg. Then, all nine
combinations of wild-type (WT), kinase-deficient (KD), and
constitutively active mutants (CA) of Jak1 and Jak3 were stably
expressed from the bidirectional pBOF-vector in U4C-IL-2Rbg-
TetOn-FlpIn cells (see Table 3 for constructs used). The trans-
fected vector inserts into a Flp recombinase target (FRT) site
and consequently, the different mutants are expressed from
the same site in the genome. Induction by doxycycline (Dox)
enabled the expression of controlled and equivalent levels of
both Jaks, dependent on the Dox concentration used. At the
Dox concentration of 5 mg/ml the expression of Jak1 was about
2-fold the endogenous levels seen in 2C4 cells, the parent cells
from which the U4C cells were derived (see Figure S2 in the
supplemental material). All nine cell lines were investigated
with respect to their ability to induce STAT5 phosphorylationTable 3. The Jak Constructs Used
Construct Abbreviation Function
Jak1WT WT Wild-type
Jak1K908A KD Kinase deficient
Jak1V658F CA Constitutively active
Jak1M956G AS Analog sensitive
Jak3WT WT Wild-type
Jak3K855A KD Kinase deficient
Jak3A572V CA Constitutively active
Jak3M902G AS Analog sensitive
See also Figure S2.
Chemistry & Biology 18, 3upon IL-2 stimulation as indicated. Figure 2A shows a represen-
tative western blot (see Figure S3) and Figure 2B the quantitation
of four western blots.
In Jak1WT/Jak3KD-cells the IL-2-induced STAT5 phosphory-
lation was reduced by 50% compared with Jak1WT/Jak3WT-
cells, while STAT5 was not phosphorylated at all in Jak1KD/
Jak3WT-cells (lanes a-c in Figures 2A and 2B). The combination
Jak1CA/Jak3CA led to constitutive IL-2-independent STAT5
phosphorylation (lane h in Figures 2A and 2B). Expression of
Jak3CA translated into constitutive phosphorylation of STAT5
only when combined with Jak1WT, but not when combined
with Jak1KD (lanes e and f in Figures 2A and 2B). The phos-
pho-STAT5 signal was reduced to about 50% in Jak1CA/
Jak3KD cells compared with Jak1CA/Jak3WT cells (lanes g
and i in Figures 2A and 2B).
Thus, we conclude that for both IL-2-dependent and constitu-
tive Jak signaling, Jak1 catalytic activity plays an essential role
while Jak3 activity is not necessary although a decrease in inten-
sity was associated with the loss of Jak3 activity (Figures 2A and
2B). It is noteworthy that constitutively active Jak1 could phos-
phorylate STAT5 independently of Jak3 kinase activity while the
inverse was not the case (lanes i and e in Figures 2A and 2B).
Jak3 Phosphorylates Jak1 but Does Not Induce STAT5
Phosphorylation
Lysates of the stable transfectants treated as described
above were investigated for Jak1 and Jak3 phosphorylation (Fig-
ure 2; Figure S4). Upon expression of Jak1WT/Jak3KD or the
‘‘inverse’’ pair Jak1KD/Jak3WT, only the kinase-deficient Jak
was phosphorylated (a, b, and c in Figure 2C), i.e., in these
combinations Jak1 phosphorylated Jak3 and vice versa. Note
that only Jak1WT/Jak3KD could mediate STAT5 phosphoryla-
tion. No Jak or STAT5 phosphorylation was observed in
Jak1KD/Jak3KD cells (d in Figure 2C).
When the constitutively active Jak1CA or Jak3CA were
combined with each other or with their corresponding WT coun-
terpart, constitutive Jak1 and Jak3 phosphorylation was
observed which, however, could further be enhanced by IL-2
stimulation (a, g, f, and h in the right panel of Figure 2C).
In contrast, when Jak1CA and Jak3CA were paired with the
corresponding inactive counterpart, no constitutive phosphory-
lation (Jak1KD/Jak3CA) or a very weak phosphorylation
(Jak1CA/Jak3KD) was observed (e and i in the left panel ofDescription
Mutation of the ATP coordinating lysine.
Activating mutation found in T and B cell lymphomas
(Jeong et al., 2008; Mullighan et al., 2009; Staerk et al., 2005).
Gatekeeper residue Met 956 mutated to Gly.
Mutation of the ATP coordinating lysine.
Activating mutation found in AMKL
(Malinge et al., 2008; Walters et al., 2006).
Gatekeeper residue Met 902 mutated to Gly.
14–323, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 317
Figure 2. Investigation of the Contributions
of Jak1 and Jak3 in a Reconstituted Cell
System Expressing Different Combinations
of Jak1/Jak3 Mutants
(A) U4C-IL-2Rb/g-FlpIn-TetOn cells expressing
different combinations of Jak1 and Jak3 mutants
were induced with 5 mg/ml Dox for 48 hr and
stimulated with 1000 U/ml of IL-2 for 15 or 60 min
as indicated. Western blots were probed with
antibodies against P-STAT5 and STAT5. Fluo-
rescently labeled secondary antibodies were used
and the signals were quantified as described in
Experimental Procedures.
(B) Results of the quantitation of four experiments
performed as in (A). The P-STAT5 signals were
represented as percent of the 15 min IL-2-stimu-
lated P-STAT5 signal obtained for cells expressing
Jak1WT/Jak3WT. The abbreviations are as shown
in Table 3. Standard deviations are shown.
(C) Phosphorylation of the Janus kinases in the
context of different combinations of Jak1/Jak3
mutants. U4C-IL-2Rb/g-FlpIn-TetOn cells ex-
pressing different combinations of Jak1and Jak3
mutants were induced with 5 mg/ml Dox for 48 hr
and stimulatedwith 1000 U/ml of IL-2 as indicated.
Western blotswere probedwith antibodies against
P-Jak1. The blots were stripped and consecutively
reprobed with anti P-STAT5, STAT5, Jak1 and
Jak3 antibodies. The phosphospecific Jak1 anti-
body is cross-reactive and recognizes Jak1 and
Jak3 phosphorylation equipotently.
See also Figure S3.
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Jak1 Has a Dominant Role over Jak3Figure 2C). Again only Jak1CA/Jak3KD led to a significant
constitutive STAT5 phosphorylation, despite the low phosphor-
ylation level of Jak1. However, upon IL-2 stimulation, both
Jak1CA and Jak3CA phosphorylated their corresponding coun-
terparts Jak3KD or Jak1KD. Interestingly, again the Jak1CA/
Jak3KD but not the Jak1KD/Jak3CA situation led to significant
STAT5 phosphorylation even in the absence of Jak1 phosphor-
ylation (see e and i in Figure 2C).
Taken together, thesedata lead to the followingmodel: Engage-
ment of the IL-2 receptor activates Jak1 and Jak3 kinase activity
independently of their phosphorylation state. Subsequently Jak1
and Jak3 phosphorylate each other. The role of Jak3 seems to
be restricted to thephosphorylationof Jak1,while Jak1phosphor-
ylates Jak3 as well as STAT5. The constitutively active Jak3 and318 Chemistry & Biology 18, 314–323, March 25, 2011 ª2011 Elsevier Ltd All rights reservedJak1 mutants retain the same functions
with the difference that for these hyperac-
tive kinases IL-2 stimulation is not required
for induction of STAT5 phosphorylation.
Specific Inhibition of Analog-
Sensitive Mutants of Jak1 and Jak3
Confirms that Jak3 Catalytic
Activity Is Dispensable for IL-2-
Induced STAT5 Phosphorylation
and that Jak1 and Jak3
Transphosphorylate
The contribution of the catalytic activity of
a given kinase can be investigated by
a chemical genetics approach. The ATPbinding pocket of the kinase is enlarged by mutation of the gate-
keeper residueandbecomes therebyaccessible to abulkykinase
inhibitor (1NM-PP1) which does neither fit into the ATP binding
pocket of the wild-type kinase nor into other kinases present in
the cell (Bishop et al., 2000, 2001). In both, Jak1 and Jak3, the
gatekeeper amino acidmethionine was replaced by site-directed
mutagenesis with glycine, yielding ‘‘analog-sensitive’’ kinases
AS-Jak1 and AS-Jak3 (see Table 3 for constructs used). The
resulting constructs AS-Jak1/Jak3WT and Jak1WT/AS-Jak3
were stably and inducibly expressed in the U4C-IL-2Rbg-TetOn-
FlpIn cells as described above. Stimulation of thesecellswith IL-2
resulted in phosphorylation of both STAT5 and the Jaks, confirm-
ing that the analog-sensitivemutantswere functional (lanes 2 and
5 in Figure 3).
Figure 3. Specific Inhibition of the AS-Jak3- and AS-Jak1 Mutants
U4C-IL-2Rb/g-FlpIn-TetOn cells expressing different combinations of Jak1
and Jak3 wild-type and analog-sensitive mutants were induced with 5 mg/ml
Dox for 48 hr and stimulated with IL-2 for 15 min as indicated. The mutants
were pretreated for 30 min prior to IL-2 stimulation with 1NM-PP1 (40 mM) as
indicated. Western blots were probed with antibodies against P-Jak1,
P-STAT5, STAT5, Jak1, and Jak3.
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1NM-PP1, a prototype analog-sensitive kinase inhibitor, did
not lead to reduced STAT5 phosphorylation indicating that the
inhibitor did not affect Jak1WT or Jak3WT activity (left panel in
Figure 3). Interestingly, treatment of cells expressing either
AS-Jak1/Jak3WT or Jak1WT/AS-Jak3 with IL-2 and 1NM-PP1
led to a hyperphosphorylation of the respective analog sensitive
Jak (lanes 3 and 6 in Figure 3). In addition, the trans-phosphory-
lation of Jak3 by AS-Jak1 and of Jak1 by AS-Jak3 was reduced
by 1NM-PP1. Importantly, STAT5 phosphorylation was effec-
tively inhibited by 1NM-PP1 in cells expressing AS-Jak1/
Jak3WT but not in cells expressing Jak1WT/AS-Jak3 (lanes 3
and 6 in Figure 3) again indicating that specific inhibition of
Jak3 kinase activity does not result in efficient abrogation of
signal transduction initiated by the IL-2 receptor.DISCUSSION
Based on the critical role Janus kinase 3 plays in cytokine signal
transduction and its restricted expression in immune cells, it is
believed that selective inhibitors of this enzyme would represent
a novel immunosuppressive principle with an unprecedented
safety profile. However, this hypothesis still remains to be
proven. The lack of Jak3 expression leading to a SCID pheno-
type in patients as well as knockdown experiments in cells
causing abrogation of signaling do not allow to distinguish
a potential structural role of the Jak3 protein from the catalytic
activity of the Jak3 enzyme. As Jak3 is always paired with
Jak1, the efficacy of recent pan-Jak inhibitors (equally potent
on Jak3 and Jak1), in particular, CP-690,550 (Changelian et al.,
2003; Jiang et al., 2008; Karaman et al., 2008; Kudlacz et al.,
2004, 2008, 2004; Williams et al., 2009), does not necessarily
prove that the enzymatic function of Jak3 plays a pivotal role in
signal transduction. Although a number of reports addressed
the biochemistry of Jak1 or Jak3 cytokine receptor interaction,
STAT phosphorylation or kinase activation (Cacalano et al.,Chemistry & Biology 18, 31999; Chen et al., 2000; Fujii, 2008; Gaffen, 2001; Goldsmith
et al., 1994; Haan et al., 2001, 2006, 2008; Kirken et al., 1995;
Liu et al., 1997; Macchi et al., 1995; Zhou et al., 2001; Zhu
et al., 1998), the cross-talk between the two Jak kinases and
their individual contributions to signal transduction has not
been fully understood.
The knockdown experiments suggested that the structural
integrity of the receptor/Jak1/Jak3/STAT-signaling-complex is
essential and a constitutively active mutant of Jak3 is not suffi-
cient to trigger STAT5 phosphorylation (see Figure 1). Specific
pharmacological blockade of Jak3 with the novel highly potent
and selective Jak3 inhibitor NIBR3049 did not result in potent
blockade of STAT5 phosphorylation as anticipated from the
kinase inhibition profile assuming equal contribution of the two
Jak kinases in IL-2 signal transduction. To confirm these find-
ings, we undertook a systematic analysis of the contributions
of Jak1 and Jak3 kinase functionalities to signal transduction in
a reconstituted system ensuring equivalent and about physio-
logical levels of expression of the two kinases together with the
IL-2 receptor complex. The data obtained from the stable cell
lines expressing all possible combinations of wild-type, kinase-
inactive, and constitutively active mutants of Jak1 and Jak3
pointed out a key role for Jak1 and showed that the kinase func-
tionality of Jak3 was not essential for STAT phosphorylation. In
an IL-2 receptor dependent context Jak3 activation loop tyrosine
phosphorylation was not necessary for STAT5 activation (Liu
et al., 1997), which seems to support our data. The selective
pharmacological inhibition of either Jak1 or Jak3 using analog-
sensitive (AS) mutants confirmed our observation with the novel
synthetic small molecule Jak3 inhibitor NIBR3049.
Collectively all data are consistent with a model in which Jak1
is the kinase responsible for Jak3 as well as STAT5 phosphory-
lation upon cytokine receptor activation. Since the level of STAT5
phosphorylation observed in the presence of catalytically inac-
tive Jak3 but active Jak1 is reduced to about half the levels
achieved with catalytically active Jak3, we conclude that the
role of Jak3 is to phosphorylate Jak1 (but not STAT5) thereby
enhancing its activity toward STAT5. Interestingly, earlier work
with in vitro kinase assays with immunoprecipitated Jak1 and
Jak3 had already suggested that Jak1 has an intrinsically higher
activity toward STAT5 than Jak3 (Liu et al., 1997).
Similar to most other kinases, Janus kinases are known to
become phosphorylated upon activation, and full activation
is associated with phosphorylation of residues within the
activation loop of the kinase domain. In our experiments with
the kinase-inactive and analog-sensitive-Jak mutants, we find
evidence for Jak1 and Jak3 transphosphorylation (Figures 2C
and 3) as has also been proposed before (Fujii, 2008; Liu et al.,
1997; Wang et al., 2003).
Importantly, our experiments show that Jak1 is able to phos-
phorylate STAT5 upon IL-2 stimulation even without prior phos-
phorylation by Jak3 indicating the existence of a phosphorylation
independent conformational activation of Jak1 and Jak3 upon
cytokine stimulation. Whether an unphosphorylated Jak1 kinase
domain is catalytically active is not known to date since the iso-
lated kinase domain has only been described in the phosphory-
lated state. In the published X-ray structures of both Jak1 and
Jak3 kinase domains, the Tyr are phosphorylated (Boggon
et al., 2005; Lucet et al., 2006; Williams et al., 2009) but the14–323, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 319
Figure 4. Schematic Representation of the
Proposed Sequence Of Events Leading to
STAT5 Phosphorylation through the IL-2R
Complex upon IL-2 Stimulation
Receptor engagement by IL-2 binding leads to
receptor chain rearrangement and activation of
kinase activities of Jak1 and Jak3. This step is
phosphorylation-independent (step 1 in A). Upon
this conformational activation, Jak1 is able to
phosphorylate STAT5 although it is not yet fully
activated (step 2 in B). The active but un-
phosphorylated Jaks now transphosphorylate
(step 3 in B) and are stabilized in their active state
(see phosphorylated Jaks in C). The fully active
Jak1 now leads to increased phosphorylation of
STAT5 (4 in C). The IL-2 receptor a chain has been
omitted in our reconstituted system and in the
figure as it is not essential for signal transduction.
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unphosphorylated state (P.D., H.-G.Z., unpublished data). The
data shown here suggest that in a cytokine receptor-dependent
system the kinase activities of both Jaks become activated inde-
pendently of phosphorylation, presumably by the release of
inhibitory constraints upon cytokine-induced receptor complex
aggregation. Trans-phosphorylation of the two Jaks then
induces a stabilization of their activated states, as described
for many other kinases, and promotes full signal transduction.
Jak1 herein plays the dominant role, activating both STAT5
and Jak3, while Jak3 supports signal transduction by phosphor-
ylating Jak1. A schematic illustration of the model is shown in
Figure 4. Even in the presence of constitutively activated Jak1
and Jak3, IL-2 stimulation and the associated conformational
rearrangements lead to an increase in Jak- and STAT-phosphor-
ylation (see f and g in Figures 2B and 2C) which is reminiscent of
the conformational activation of Jaks by receptor rearrange-
ments upon cytokine binding to the extracellular part of cytokine
receptors (Figure 4).
As has been reported for several kinases (Cameron et al.,
2009; Frye and Johnson, 2009; Okuzumi et al., 2009), the
analog-sensitive Jak kinases become hyper-phosphorylated in
the presence of an ATP-competitive specific inhibitor. Compa-
rable ‘‘inhibitor priming’’ of Jaks has been described in the
context of the oncogenic Jak2V617F mutant for other Jak inhib-
itors (Jak inhibitor 1 and Go¨6976) (Grandage et al., 2006; Haan
et al., 2009). Our data suggest that the kinase responsible for
the hyper-phosphorylation of AS-Jak1 is Jak3 and vice versa320 Chemistry & Biology 18, 314–323, March 25, 2011 ª2011 Elsevier Ltd All rights reserved(see Figure 2). ATP-competitive kinase
inhibitors in general often target and
block the kinase domain in the active
conformation. Since we have shown
that both Jak1 and Jak3 can phosphory-
late their Jak counterpart even though
they are not phosphorylated themselves,
it is conceivable that the inhibited
analog-sensitive Jak (presented in the
active conformation induced by the
inhibitor) is phosphorylated by its Jak
counterpart because the inhibitor stabi-lizes the active form of the cytokine/receptor/Jak complex
which is particularly prone to efficient Jak phosphorylation.
The inhibited analog-sensitive Jak cannot phosphorylate its
Jak counterpart efficiently.
The finding that Jak1 and not Jak3 kinase activity is essential in
mediating cytokine-dependent signal transduction was unex-
pected and has important consequences for drug discovery.
Based on the data shown here the concept that a highly selective
ATP-competitive Jak3 kinase inhibitor will result in the desired
safe and effective immunosuppression is questionable.
Concomitant inhibition of Jak1 kinase activity seems to be
required for suppression of gc cytokine signaling. However,
the involvement of Jak1 (in combination with Jak2 or Tyk2) in
the majority of cytokine receptor signaling via the Jak-STAT
pathway raises concerns about target-related side effects.
Unfortunately, neither specific Jak1-blocking agents nor dual
Jak1/Jak3 inhibitors (devoid of Jak2 and Tyk2 activity) are avail-
able to date which would allow the exploration of their pharma-
cological potential. In any case, clinical data from several studies
with CP-690,550 and other pan-Jak kinase inhibitors will soon
show whether this approach is safe and effective in humans.
SIGNIFICANCE
Immunosuppressive drugs are of crucial importance in
disease treatment today and more specific drugs with
minimal side effects are sought. Janus kinase 3 (Jak3) is
essential for signal transduction via cytokines utilizing the
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immunodeficiency. Jak1, however, also participates in
signaling through gc containing receptors. It is generally
assumed that specific inhibition of Jak3 kinase activity will
result in immunosuppression and because of the restricted
expression of Jak3 this will have therapeutic potential as a
selective and potentially safe immunosuppressive principle.
Surprisingly, we find that a highly potent small molecule
Jak3 kinase inhibitor showing >150-fold selectivity over the
other Janus kinases, is >20-fold less potent in abolishing
gc-cytokine (IL-2, IL-4, or IL-15)-induced STAT phosphoryla-
tion compared with pan-Jak inhibitors in several cell lines
and human lymphocytes.
To further explore this unexpected observationwe studied
IL-2 -dependent signaling in a reconstituted system using
transfectants in which all combinations of wild-type, consti-
tutively active and kinase-inactive mutants of Jak1 and Jak3
were stably coexpressed. The presence of kinase-inactive
Jak1 resulted in complete abolishment of STAT5 phosphor-
ylation regardless of the Jak3 status, whereas it was only
reduced partially in the presence of kinase-inactive Jak3.
We next generated analog-sensitive (AS) mutants of Jak1
and Jak3 which were coexpressed in the reconstituted cell
system. Again specific inhibition of AS-Jak1 but not of AS-
Jak3 by the ATP-competitive analog 1NM-PP1 abrogated
IL-2 signaling: These results corroborated the finding with
the Jak3-specific small molecule inhibitor and taken
together our results demonstrate that the two Jak kinases
involved in signaling through gc utilizing cytokine receptors
are not equally important and that Jak1 plays a dominant
role. These data challenge the concept that ATP-competi-
tive kinase inhibitors selectively targeting Jak3 will be suffi-
cient to achieve immunosuppression.EXPERIMENTAL PROCEDURES
Materials
The cytokines used were IL-2 (Peprotech or Chiron [Proleukin]), IFN-a (Immu-
notools), and IFN-g (Roche). Doxycycline (Sigma) was usually used at
a concentration of 5 mg/ml. Jak inhibitor 1 and 1NM-PP1 were purchased
from Calbiochem. CP-690,550 was purchased from Selleck Chemicals LLC
and NIBR3049 was synthesized at Novartis.
Jak Enzyme Assays
For enzyme assays affinity-purified GST fusions of the active kinase domains
(GST-Jak1(866-1154), GST-Jak2(808-1132), GST-Jak3(811-1124), and GST-
Tyk2(888-1187) were expressed in insect cells or purchased from Invitrogen
(Carlsbad, CA). All assays were performed in 384-well microtiter plates with
8 point serial dilutions of compounds. The kinase reactions were started by
stepwise addition of 4.5 ml per well of a 2 3 peptide/ATP-solution and 4.5 ml
per well of a 2 3 enzyme solution. The constitution of the assay buffer was:
50 mM HEPES (pH 7.5), 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6%
DMSO, 10 mM beta-glycerophosphate, and 10 mM sodium orthovanadate.
The other components were adjusted specifically for the respective kinase
assay: Jak1: 16 nM enzyme, 70 mM ATP, 2 mM peptide substrate, 12 mM
MgCl2. Jak2: 1.8 nM enzyme, 20 mM ATP, 2 mM peptide substrate,
9 mM MgCl2. Jak3: 13 nM enzyme, 18 mM ATP, 2 mM peptide substrate,
1.5 mM MgCl2. Tyk2: 3.5 nM enzyme, 35 mM ATP, 2 mM peptide
substrate, 9 mM MgCl2. The stop solution was 100 mM HEPES (pH 7.5_,
5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35.
The peptide substrate used in the Jak1 and Tyk2 assays was FITC-Ahx-
KKSRGDYMTMQIG-NH2 and Carboxyfluorescein-Ahx-GGEEEEYFELVKKKKChemistry & Biology 18, 3for the Jak2 and Jak3 assays. Kinase reactions were incubated at 30C for
60 min and terminated by addition of 16 ml per well of stop solution. Phosphor-
ylated and unphosphorylated peptides were separated using the Caliper
microfluidic mobility shift technology on a Caliper LC3000 workstation and
kinase activities were calculated from the amounts of formed phosphopeptide.
Knockdown of Jak1 and Jak3 with si-RNA
The Cell Line Nucleofector kit V and the Amaxa Nucleofector electroporation
apparatus (Lonza) were used and the cells were treated according to the
manufacturer’s instruction. Human Jak1 or Jak3 validated stealth oligo duplex
1 + duplex 2, or si-RNA negative (medium GC duplex) or fluorescein-labeled
si-RNA positive control (all from Invitrogen) were used. The efficiency of the
transfection and the response to cytokines (IL-2, IFN-a) were assessed at
24 hr or 48 hr after transfection.
Assessment of STAT Phosphorylation By Flow Cytometry
Cells treatedwith inhibitor for 30min at 37Cor untreated cells were stimulated
with 20 U/ml IL-2 for 15 min at 37C, fixed with paraformaldehyde (final
concentration 2%), permeabilized with 90% methanol on ice, washed, and
stained with Alexa647-labeled anti-STAT5-pY694 (BD Biosciences) for
45 min followed by analysis on a FACS Calibur flow cytometer (BD Biosci-
ences). IC50 values for inhibitors were calculated based on an 8 point concen-
tration-response curve. Recombinant human IFN-a or IFN-g (Immunotools,
Berlin), were used to stimulate STAT1 phosphorylation which was assessed
following the same protocol but using PE-labeled anti-STAT1-pY701 antibody
(BD Biosciences).
Expression Plasmids
Standard cloning procedures were performed throughout. The generation of
pBOF is described in the supplemental information (Supplemental Experi-
mental Procedures and Figure S2B). Starting from pBOF-Jak1WT/Jak3WT,
the mutants Jak1V658F/Jak3WT (CA/WT), Jak1K908A/Jak3WT (KD/WT),
Jak1V658F/Jak3A572V (CA/CA), Jak1WT/Jak3A572V (WT/CA), Jak1K908A/
Jak3A572V (KD/CA), Jak1WT/Jak3K855A (WT/KD), Jak1K908A/Jak3K855A
(KD/KD), Jak1V658F/Jak3K855A (CA/KD), Jak1M956G/Jak3WT (AS/WT),
and Jak1WT/Jak3M902G (WT/AS) were generated by point mutagenesis
using the QuikChange XL site-directedmutagenesis kit (Agilent Technologies).
The constructs pEF6-V5-His-hIL2Rb and pTetOn-hIL2Rg-IRESpuro are
described in the Supplemental Experimental Procedures.
Cell Lysis, Immunoprecipitation, and Western Blot Analysis
All steps of cell lysis, immunoprecipitation, and western blot analysis were per-
formed as described (Radtke et al., 2005; Vollmer et al., 2009). Anti-phospho-
STAT5 (BD Biosciences), anti-phospho-Jak1 (Tyr1022/Tyr1023, Santa Cruz
Biotech.), anti-Jak1 (BD Biosciences), anti-Jak3 (Santa Cruz Biotech.) and
anti-STAT5 (Santa Cruz Biotech.) were used for western blot detections. For
a further characterization of the anti-phospho-Jak1 (Tyr1022/Tyr1023) anti-
body used to detect phosphorylated Jak1 and Jak3, see Figure S4. ECL detec-
tion of western blots was performed as described (Haan and Behrmann, 2007)
with horseradish peroxidase-conjugated secondary antibodies from Dako or
Cell Signaling. For western blot quantitation IRDye 680 anti-mouse IgG
(LI-COR) and Dylight 800 anti-rabbit IgG (Pierce) were used for detection on
the Odyssey instrument (LI-COR). For quantification the average signals of
four blots were determined. Anti-phospho-STAT5 (BD Biosciences) and anti-
STAT5 (Santa Cruz Biotechnology) were used as primary antibodies. The
STAT5 signals served for normalization of phospho-STAT5 levels. Quantitation
was performed on single channels with the analysis software V3.0 provided by
the manufacturer (Li-COR Biosciences). The signals to be quantitated were
normalized with respect to the loading control for each lane and the signal
intensity was then represented as fold induction or as percentage of the stron-
gest signal.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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